RTS,S to be the worlds first vaccine against malaria, developed by GSK
Published By : 24 Jul 2014 | Published By : QYRESEARCH
British drug maker GlaxoSmithKline, aims at coming up with a vaccine against malaria specially developed for children in Africa. For this, GSK has applied for consent from regulatory authorities. The vaccine is known as RTS,S which is meant to be used outside of the European Union even though its evaluation is to be carried out by the European Medicines Agency (EMA) in accordance with the World Health Organization (WHO).
On an annual basis, malaria causes 600,000 deaths out of which maximum constitutes the population of babies in the Sub-Sahara African region.
Scientists at GlaxoSmithKline have been working towards developing a vaccine for malaria for almost three decades.
Unfortunately, when the RTS,S shot was tried on babies between the age group of six to twelve weeks, it was observed that this vaccine provided marginal protection. This showed that RTS,S could be relied upon to be providing 100% effectiveness against malaria.
This vaccination was tried across thirteen research centers in places like Malawi, Mozambique, Ghana, Kenya, Gabon, Burkina Faso, Nigeria and Tanzania.
GSK also stated that in addition to immunization, other measures like anti-malarial drugs and bed nets need to be used for effective malaria control.
The nonprofit PATH Malaria Vaccine Initiative (MVI) and GSK have been working in close collaboration with each other to come up with the RTS,S and it was funded by the Bill and Melinda Gates Foundation.
If this vaccine gets approved, it the price will only include the cost of production and the margin of 5% will be invested for further research in this area.